Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Amyloidosis: Diagnosis, Treatment, Outcomes.
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
Deciphering the genetics and mechanisms of predisposition to multiple myeloma
Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population‐based screening study
Prevalence of smoldering multiple myeloma based on nationwide screening
Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study
The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study
Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Comorbidities in multiple myeloma and implications on survival: A population‐based study
Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma
Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study
Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Fractures and survival in multiple myeloma: results from a population-based study
Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms
Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma